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BACKGROUND. The specific activity of the non-receptor protein tyrosine kinase, Src,
is increased in the majority of colon and rectal adenocarcinomas compared to
normal mucosa. However, the prognostic significance of this difference is un-
known. The objective of the current study was to determine if Src activity is a
marker for poor clinical prognosis in colon carcinoma patients. As Src activation
leads to expression of urokinase/plasminogen activator receptor (u-PAR), expres-
sion of Src and u-PAR were correlated with patient survival.
METHODS. Tumors and adjacent normal colonic mucosae from 45 patients with
colorectal carcinoma were screened for Src activity by the immune complex kinase
assay. Expression of u-PAR was determined by enzyme linked immunoabsorbent
assay. The primary tumor-to-normal mucosa ratios of activity were compared
following classification and regression tree (CART) analysis to determine the prog-
nostic significance of elevated specific Src activity. Expression of u-PAR was cor-
related with Src activity.
RESULTS. By CART analysis, Src activity in tumors elevated more than twofold over
normal mucosa was significant. Increased Src activity significantly correlated with
Dukes stage, pT and pN classification, and increased u-PAR levels (P  0.001).
Kaplan Meier analysis showed a significant association between elevated Src
activity and shorter overall survival of all patients (P  0.0004) and of Dukes Stage
A-C patients (P  0.0037). In patients who underwent curative resection, a signif-
icant correlation with a decreased disease-free survival rate was found (P
 0.0001). Multivariate analysis revealed that elevated Src activity was a prognostic
parameter independent of M classification (P  0.0125, relative risk 3.54, 95%
confidence interval 1.31 – 9.76).
CONCLUSIONS. Src activity is an independent indicator of poor clinical prognosis in
all stages of human colon carcinoma. These data suggest that Src-specific inhibi-
tors may have a therapeutic role in inhibiting tumor progression and metastasis,
and that measurement of Src activity may aid in selection of early stage patients for
adjuvant therapy. Cancer 2002;94:344 –51. © 2002 American Cancer Society.
KEYWORDS: Src, urokinase-type plasminogen activator receptor, colorectal carci-
noma, protein tyrosine kinase.
The non-receptor protein tyrosine kinase, Src, is the archetype of anine-member family of highly related protein tyrosine kinases
(PTKs). Src family PTKs function in signaling pathways regulating
diverse cellular functions including proliferation, migration, cytoskel-
etal reorganization, and cellular survival by interacting with and/or
phosphorylating specific substrates (reviewed by Thomas and
Brugge).1 The retroviral form of Src (v-Src) has long been studied for
its ability to induce malignant transformation of mammalian cells in
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tissue culture and to induce metastatic tumors in an-
imals (reviewed by Bishop).2 Additionally, in animal
models, considerable evidence has implicated activa-
tion of “normal” c-Src in tumorgenicity. For example,
association of c-Src with polyoma middle T antigen
leads to increased specific activity of Src, and is re-
quired for malignant transformation by polyoma vi-
rus.3,4 Increased specific activity of c-Src has been
observed in a number of human tumors, most com-
monly occurring in colon,5–11 breast,12 and ovarian13
carcinomas. When Src expression and activity is de-
creased in specific colon14 and ovarian13 carcinoma
cell lines, corresponding decreases in tumorgenicity in
nude mice are observed.
Deregulation of multiple pathways that contribute
to tumorgenicity may be affected by Src activation.
Ellis et al.15 showed that Src activity regulates consti-
tutive as well as hypoxia-induced vascular endothelial
growth factor expression in colon adenocarcinoma
cells. Pories et al.16 directly showed that transfection of a
colonic cell line with Src conferred a higher invasive
capacity to these cells. Proteolytic enzymes, which in
part mediate invasion such as MMP-9,17 cathepsin-L,18
or u-PA,19,20 are induced by v-Src. Furthermore, ex-
pression of activated Src in colon carcinoma cell lines
leads directly to increased transcription and expres-
sion of the urokinase-type plasminogen activator re-
ceptor gene,21 resulting in increased ability to proteo-
lytically cleave laminin, a component of basement
membranes which is degraded in the process of me-
tastasis.
Activation of c-Src occurs most frequently in hu-
man colon and rectal adenocarcinomas. Increased Src
activity has been observed during both development
and progression of the disease. Src activity increases
in stages of tumor development as in dysplastic polyps
with high malignant potential relative to more benign
adenomas.8 Patients with ulcerative colitis commonly
display increased Src activity compared to normal or
inflammatory colonic mucosa.22 Nearly 80% of pri-
mary colon tumors express Src with abnormally high
specific activity, and further increases in activity are
common in distant metastases relative to the corre-
sponding primary tumors.
To our knowledge, the potential prognostic signif-
icance of Src activation in human colon tumors has
not yet been investigated. Therefore, in a series of
colorectal carcinoma patients, we prospectively inves-
tigated the significance of elevated specific Src activity
as an indicator of clinical prognosis. Moreover, since
Src induces urokinase/plasminogen activator receptor
(u-PAR) expression,21 an important molecule in inva-
sion of colon tumor cells23–26 and a prognostic marker
of patient survival,27 a second study objective was to
compare Src activity, u-PAR expression, and progno-
sis. The current study provides evidence that specific
Src activity is an independent predictor of clinical
prognosis for colorectal carcinoma patients and cor-
relates with u-PAR-gene expression. These findings
implicate Src as a new potential target for anti-meta-
static cancer therapy.
MATERIALS AND METHODS
Patients and Tumors
Samples of colorectal adenocarcinomas and adjacent
normal colonic mucosae were available from 45 pa-
tients who underwent primary tumor resection be-
tween 1990 and 1994 at The University of Texas M. D.
Anderson Cancer Center. The mean patient age was
63.8 years (range 35 to 86 years); 30 patients were
male, and 15 were female. Of these 45 patients, 28
(62% ) underwent tumor resection with curative intent
(R0 resection, 22 patients Dukes Stage A-C, 6 patients
Dukes Stage D). The remaining 17 patients (38% )
underwent palliative resection of the primary cancer;
all patients in this group had macroscopic residual
metastatic tumor (R2 resection, all 17 patients Stage D
disease). Tumors were located in the colon (n  32) or
rectum (n  13). Relevant tumor and stage character-
istics are provided in Table 1.
Prospective follow-up was done 6, 12, 18, and 24
months after surgery and at one-year intervals there-
after in all patients. Follow-up included physical ex-
amination, abdominal and pelvic computed tomo-
graphic scans, colonoscopy, chest X-ray, hematology,
TABLE 1
Characteristics of Colon Tumors Analyzed for Src Activity
Dukes stage A 1a
B 12
C 9
D 23
Pathologic T classification T1 1
T2 5
T3 24
T4 15
Pathologic N classification N0 17
N1 28
M classification M0 22
M1 23
Histologic grade G1 4
G2 34
G3 7
Tumor location Cecum/right hemicolon 12
Transverse colon 1
Left hemicolon 7
Sigmoid colon 13
Rectum 12
a Number of patients with indicated characteristic
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blood chemistry, and screening for the tumor markers
carcinoembryonic antigen and CA 19-9. If tumor re-
currence was suspected in Dukes Stage A-C patients,
the patient was recommended for confirmation of
diagnosis by biopsy or exploratory surgery. Imaging
procedures and elevated serum tumor marker levels
were accepted for the diagnosis of disease recurrence
if pathologic evidence of recurrence was not feasible.
Causes of death were evaluated clinically.
Src Expression and Activity Assays
Tumors and corresponding normal mucosae were
snap-frozen at the time of resection and stored in
liquid nitrogen. Samples were prepared and assayed
as described previously.10 Briefly, normal colonic mu-
cosal and adenocarcinoma tissues were separated
from underlying muscle by blunt dissection. Light mi-
croscopy evaluation showed that the separation oc-
curred at the level of muscularis mucosa. Histopatho-
logic examination was performed on all tumors to
confirm that the primary tumor origin was colonic.
Samples were homogenized in radioimmunoprecipi-
tation assay (RIPA) buffer A (1% triton X-100, 0.1%
sodium dodecyl sulfate [SDS], 0.5% deoxycholate, 150
mM disodium chloride, 5 mM sodium pyrophosphate,
20 mM sodium phosphate, pH 7.4) using a Polytron
homogenizer (Brinkman Instruments, Westbury, NY).
Protein in clarified lysates was estimated by the bicin-
choninic (BCA) protein assay (Pierce Chemical Co.,
Rockford, IL). For determination of relative Src activ-
ity, the immune complex kinase assay was employed.
Aliquots of lysate containing 200 g of protein were
incubated with mAb 327 (Oncogene Sciences, Mine-
ola, NY) for 2hours at 4 °C, followed by a similar
incubation with 6 g rabbit anti mouse immunoglob-
ulin G, then 50 L 10% (vol/vol) Pansorbin (Calbio-
chem, La Jolla, CA) as described previously.10 Immu-
noprecipitates were washed three times and
resuspended in reaction buffer containing 10 mM
magnesium chloride, 20 mM Hepes, 100 mM sodium
vanadate, 10 Ci [-32P ATP] and 5 g of acid-dena-
tured rabbit muscle enolase (Sigma Chemical Co., St.
Louis, MO). Reactions were allowed to proceed for 10
minutes at 25 °C and terminated using a final buffer
consisting of 2% SDS, 5% -mercaptoethanol, 0.125 M
Tris (pH6.8), 1 mM ethylenediamine tetraacetic acid,
10% glycerol, and 0.02% bromophenol blue. Proteins
were resolved on 8% SDS-polyacrylamide gels, and
radiolabeled proteins were detected and relative pro-
tein intensities were determined by densitometric
scanning as described previously.10
Determination of U-PAR Expression
The expression of u-PAR protein was determined by
enzyme linked immunoabsorbent assay (ELISA). Ly-
sates of the resected tissue were prepared and assayed
as described by the manufacturer (American Diagnos-
tica, Greenwich, CT).
Statistical Analyses
For determination of cutoff points for the definition of
elevated Src activity and for the u-PAR amounts as
measured by ELISA, classification and regression tree
analysis (CART) was performed.28 CART is a structured
classification method allowing the determination of a
cut point by recursive partitioning of a learning sam-
ple.28 Chi-square analysis was performed to determine
the correlations between expected and detected fre-
quencies, considering the parameters as follows: Src
activity (dichotomized at 2.1 or higher according to
CART analysis), gender (male vs. female), age (dichot-
omized at median), tumor location (colon vs. rectum),
surgical curability (R0 vs. R2), and pT, pN, M classifi-
cation and Dukes stage. Group-oriented life-table
curves were calculated with Kaplan-Meier analysis
and compared with the Mantel-Cox log rank statis-
tics.29 To correct the univariate prognostic relevance
of Src activity for its correlation with established risk
factors in colon carcinoma, multivariate analysis was
performed using the Cox proportional hazard model.30
Parameters for multivariate analysis were considered
as stated for chi-square analysis. The parameters were
entered into the multivariate model after a significant
univariate P value had been calculated. All statistics
were two-sided at a significance level of P  0.05,
using the BMDP statistical software (Statistical Solu-
tions, Saugus, MA).31
RESULTS
The 45 colorectal carcinoma patients were followed
prospectively for a median of 36 months (range 1-96
months) after primary tumor resection. Of those pa-
tients, 28 underwent curative (R0) resection. During
the study time, 31 of 45 patients died, 30 from tumor-
related causes. In the 28 curatively resected patients,
21 recurrences occurred, 11 of which were liver me-
tastases only and 10 of which were multiple metasta-
ses (nine in the liver and lung, one a local recurrence
and lung metastisis). An overview of the tumor char-
acteristics for all 45 patients is provided in Table 1. All
resected tumors were adenocarcinomas.
Correlation of Elevated Src Activity with Established
Tumor Characteristics
To determine the optimal cutoff point for Src activa-
tion, CART analysis was performed (log rank test, P
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 0.05).28 The optimal Src activity cutoff point in the
tumor was 2.1 times the level in normal mucosa; this
level of increase is consistent with increases in Src
previously considered biologically relevant.10 Applying
this criterion to the current patient sample, significant
correlations (chi-square) were observed between in-
creased Src-kinase activity and primary tumor classi-
fication pT, pN, and Dukes stage (Table 2). Median
specific Src activity in the tumor tissues was 2.9 times
the activity in the corresponding normal mucosa
(range 0.3 - 57.0 times normal mucosa activity).
Correlation of Elevated Src Activity with Endogenous
Amounts of u-PAR Protein
In a previous study, we showed that Src activity was
proportional to the expression of u-PAR, an invasion-
related molecule shown to be of functional and prog-
nostic relevance in colon carcinoma.27 We therefore
tested for a correlation of endogenous Src activity with
u-PAR levels in the current patient series. In 17 sam-
ples, an additional ELISA analysis for endogenous
amounts of urokinase receptor was performed. Con-
sistent with previous results, a high level of u-PAR (3.2
ng/mg tissue, according to CART analysis) in the pri-
mary tumor was predictive of a significantly shorter
overall survival as determined by Kaplan-Meier anal-
ysis and Mantel-Cox log rank-statistics (Fig. 1). In lin-
ear regression analysis, the specific Src activity in
these samples showed a significant correlation with
endogenous u-PAR-amounts (P  0.001, Pearson’s
correlation coefficient: 0.8487, Figure 2).
Analysis of Univariate Prognostic Impact of Increased
Src Activity
Because of the ability of Src activation to lead to in-
creased expression of u-PAR, we next determined if
FIGURE 1. Survival of patients with and without elevated levels of urokinase/
plasminogen activator receptor (u-PAR). Relative u-PAR levels in tumor tissues
were determined by enzyme linked immunoabsorbent assay as described. In
the graph, the survival times of 12 patients with less than 3.2 ng u-PAR/mg
tumor tissue (upper curve) are compared to 5 patients with greater than 3.2 ng
u-PAR/mg tumor tissue (lower curve). For the 12 patients with less than 3.2 ng
u-PAR/mg tissue, the mean survival time was 46.8 months (standard deviation
[SD], 11.5). For the 5 patients with greater than 3.2 ng u-PAR/mg tumor, the
mean survival time was 14.2 months (SD, 6.0). The differences in survival are
significant (P 0.05, Mantel-Cox log rank). The 3.2 ng u-PAR/mg tumor tissue
as an estimate of significantly increased u-PAR expression was determined by
classification and regression tree analysis.
FIGURE 2. Linear regression analysis demonstrating the correlation between
endogenous urokinase/plasminogen activator receptor amounts (ng/mg tissue,
enzyme linked immunoabsorbent assay) and specific Src activity in resected
colon cancers. The correlation is highly significant with P  0.001 (Pearson
correlation coefficient: 0.8487).
TABLE 2
Comparison of Established Patient and Tumor Prognostic Factors
with Two-fold or Greater Src-Activity (Chi-Square)
Parameter
Significance of 2-fold or
greater Src-activitya
Gender NS
Age (dichotomized at median) NS
Dukes stage 0.0468
Pathologic T classification 0.0071
Pathologic N classification 0.0137
M classification NS
Pathologic grade NS
Tumor location (colon vs. rectum) NS
R (surgical curability) NS
a All significant correlations are positive correlations.
NS: not significant.
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Src activation itself was a marker for clinical progno-
sis. The cohort of patients with a 2.1 fold or greater
increase in Src activity in their tumors was found to
have a poor overall survival (Kaplan-Meier survival
analysis, Mantel-Cox log rank test, P  0.0004, Figure
3). Further, the patients who underwent curative (R0)
resection who had a 2.1 fold or greater increase in Src
activity were found to have significantly decreased
disease-free survival (n  28, P  0.0001). To deter-
mine if Src activation was a prognostic marker for
patients presenting without distant metastases, we an-
alyzed the results from Dukes Stage A-C tumors only.
As shown in Figure 4, a 2.1 fold or greater increase in
Src activity also was associated with a decreased over-
all survival for these patients (P  0.0037). These re-
sults suggest that a high endogenous Src activity in the
primary tumor as compared to normal mucosa is a
significant prognostic marker in colorectal carcinoma.
Analysis of Multivariate Prognostic Impact of Elevated
Src Activity
To correct the univariate results for correlations with
established risk factors in colon carcinoma, multivar-
iate analysis was performed for the overall survival of
all 45 patients (Cox proportional hazard model) with
intended surgical curability (R0 versus R2), Dukes
stage, pT, pN, M classification and tumor location
(colon/rectum), and covariates (Table 3). In this anal-
ysis, an elevated Src activity of more than 2.1 fold was
an independent prognostic indicator of survival dis-
tinct from the presence of metastasis (P  0.0125,
relative risk as estimated by odds ratio 3.54, 95% con-
fidence interval [CI] 1.31 - 9.76). Elevated Src activity
was also an independent factor in Dukes’ A-C patients
for overall survival (P 0.0150, relative risk 20.82, 95%
CI 1.80 - 240.60) and in R0 patients for disease-free
survival (P  0.0034, relative risk 11.53, 95% CI 2.23 -
59.09). Taken together, these results strongly imply
that Src activity in the primary tumor is a prognostic
marker for patient survival.
DISCUSSION
Several studies from our laboratory9,10 and others6-8,11
have shown that Src activation is common throughout
the development and progression of human colon
carcinoma. Higher activities of Src are common in
FIGURE 3. Survival of all colon carcinoma patients with or without Src
activation. The relative Src activity was determined as the ratio of activity in
tumors to adjacent normal mucosa, as described. In the graph, the survival
times of 17 patients whose tumors had Src activities less than 2.1 fold relative
to normal mucosa (upper curve) are compared to those of 28 patients with a
greater than 2.1 fold increase in Src activity (lower curve). For the 17 patients
expressing Src activity at a level less than 2.1 times that of normal colonic
mucosa, mean survival time was 68.6 months, standard deviation (SD)  9.1
months. For the 28 patients with tumors expressing Src activity increased by
greater than 2.1 fold, the mean survival time was 27.8 months, SD  4.5
months. The survival difference between the groups is significant (P 0.0004,
Mantel-Cox analysis). The significance of a 2.1 fold increase in Src activity was
determined by classification and regression tree analysis.
FIGURE 4. Survival of patients with Dukes Stage A-C tumors with or without
Src activation. Relative Src activities were determined as described in Figure 3.
In the graph, the survival of 11 patients with Src activity less than 2.1 fold
greater than normal adjacent mucosa (upper curve) is compared to 9 patients
with a greater than 2.1 fold increase in Src activity relative to adjacent normal
mucosae (lower curve). None of these patients had evidence of distant me-
tastasis (Dukes Stage D) at the time of resection of their primary colorectal
carcinoma. For the 11 patients presenting with tumor Src activity less than 2.1
fold that of the normal mucosae, the mean survival time was 84.2 months
(standard deviation [SD], 7.7 months). For the nine patients with increased Src
activity, mean survival time was 43.7 months (SD, 7.7 months). The survival
difference between the two groups is significant (P  0.0037, Mantel-Cox
analysis).
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metastases relative to primary tumors.10,32,33 These
results suggest that increased Src activity confers a
selective advantage in growth and/or survival of colon
tumor cells. In the current analysis of 45 patients, we
show that increased Src activity in primary tumors is
associated with significant decreases both in disease-
free intervals and in overall survival of colorectal car-
cinoma patients. Specifically, using CART analyses,
Src activation was defined as a greater than twofold
increase in activity in tumor tissue relative to adjacent
normal tissue, similar to Src increases considered sig-
nificant in previous studies.10 By this criterion, Src
activation was equally predictive of patient outcome
irrespective of the presence of metastasis at the time
of initial surgery. Thus, deregulation of Src activity
may be one of critical events in the development of
metastases from colon tumors.
As yet, the mechanism by which Src is activated in
colon tumors and metastases is unclear. In a subset of
hepatic colorectal carcinoma metastases, Irby et al.34
reported a truncating mutation at codon 531 in 12% of
the samples they analyzed. The truncation led to in-
creased specific activity of Src, and expression of this
mutated form of Src led to transformation of NIH 3T3
cells. However, this mutation was not observed in
other studies of diverse and much larger patient pop-
ulations,35–37 suggesting that this mutation is rare and
cannot account for the increased activity of Src found
in the majority of metastases. In normal cells, Src is
activated by association with other signaling mole-
cules, including growth factor receptors such as c-Met,
and focal adhesion kinase, both of which are overex-
pressed in human colon tumors.38,39 Irrespective of
the mechanism of Src activation, increases in total
enzymatic activity are due largely to increased specific
activity, not overexpression of Src in either colon tu-
mors (reviewed by Jessup and Gallick).40 Recently,
similar results have been observed in bladder tumors
in which Src is activated,41 suggesting that activation
of Src occurs most commonly through deregulation of
signaling pathways as opposed to mutational activa-
tion. Thus, in the current study, each tumor was ana-
lyzed for activity of Src in the standard immune com-
plex kinase assay. This technique has several
limitations, including the requirement of approxi-
mately 200 g of protein from tissue. For this reason,
the sample size in the current study is smaller than in
other studies that employ immunohistochemic tech-
niques to detect overexpression of potential marker
proteins. Immunohistochemic techniques have the
potential advantage of visualizing individual cells;
thus, questions of heterogeneity can be addressed.
Therefore, we are currently investigating whether an-
tibodies recognizing specific Src phosphorylation sites
might be able to detect activated Src in individual
cells.
The current study suggests further that specific
substrates of Src might be candidate prognostic mark-
ers for colon carcinoma. One such substrate,
p120(ctn), which by association with E-cadherin par-
ticipates in cell-cell adhesion, was shown to be down-
regulated in 86% of 44 primary colorectal carcinomas,
with downregulation correlating with advanced stage
of disease and decreased survival.42 Whether phos-
phorylation of this protein by Src decreases its half-life
was not examined. Alternatively, enzymes involved in
Src activation have potential as markers of tumor pro-
gression. In this regard, the expression of N-myristoyl-
transferase, an enzyme catalyzing myristoylation of
Src (required for membrane association and activation
of Src) is increased in gallbladder carcinomas, and this
increase correlated with decreased mean survival
times in these patients.43
Finally, an understanding of alterations in funda-
mental pathways regulating adhesion and migration
as a result of Src activation may be important not only
in defining the mechanism by which Src activation
contributes to tumor progression, but may also serve
as a potential prognostic marker. For example, Src
activation leads to deregulation of adhesion molecules
and associated pathways such as E-cadherin/beta-
catenin44 (reviewed by Noe et al.),45 leading to rear-
rangement of cell-cell contacts resulting in increased
migration of cells. Src activation has been shown to
induce diverse proteases such as cathepsin L,18,46
MMP-9,17 u-PA,19,20 MT1-MMP, and TIMP-147 in var-
ious tumors. In colon tumors, we previously showed
that Src activation leads to increased u-PAR expres-
sion,21 further corroborated by the current clinical
study. For u-PAR, there is not only evidence for a
transcriptional regulation by Src21 but also for a recip-
TABLE 3
Multivariate Analysis of Survival of All 45 Patients Including All
Parameters that were Significant in Univariate Analysis (Cox
Proportional Hazard)
Parameter
Multivariate
P-value
Relative risk
(odds ratio)
95% confidence
interval
Src-activity two-fold or higher in
tumor tissue 0.0125 3.54 1.31–9.76
Dukes stage NS — —
Pathologic T classification NS — —
Pathologic N classification NS — —
M classification 0.0151 3.78 1.27–9.39
Tumor location (colon vs. rectum) NS — —
R (surgical curability) NS — —
NS: not significant in multivariate analysis.
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rocal regulation of Src-family kinases by ligand-bound
u-PAR at the protein level.48,49 These results suggest
the possibility of a positive-regulatory feedback be-
tween u-PAR and Src kinases that might augment a
tumor cell’s invasive capability.
The presentation in the current study that Src
activation is associated with invasion and metastasis
as well as poor clinical prognosis suggests that this
protein tyrosine kinase is a promising target for devel-
opment of inhibitors as potential therapeutic agents
for colon carcinoma. Indeed, inhibition of Src has
been shown to inhibit growth in nude mice of HT 29
colon tumor cells14 and u-PAR-mediated proteolysis
of SW480 cells expressing activated Src.21 As other Src
family members such as Fyn and Yes perform many of
the normal functions of Src itself, selective inhibitors
may also lead to less serious toxicity than traditional
regimens of chemotherapy.
REFERENCES
1. Thomas SM, Brugge JS. Cellular functions regulated by Src
family kinases. Annu Rev Cell Dev Biol 1997;13:513-609.
2. Bishop JM. Molecular themes in oncogenesis. Cell 1991;64:
235-48.
3. Kiefer F, Courtneidge SA, Wagner EF. Oncogenic properties
of the middle T antigens of polyomaviruses. Adv Cancer Res
1994;64:125-57.
4. Guy CT, Muthuswamy SK, Cardiff RD, Soriano P, Muller WJ.
Activation of the c-Src tyrosine kinase is required for the
induction of mammary tumors in transgenic mice. Genes
Dev 1994;8:23-32.
5. Bolen JB, Veillette A, Schwartz AM, Deseau V, Rosen N.
Activation of pp60c-src protein kinase activity in human
colon carcinoma. Proc Natl Acad Sci USA 1987;84:2251-5.
6. Bolen JB, Veillette A, Schwartz AM, Deseau V, Rosen N.
Analysis of pp60c-src in human colon carcinoma and nor-
mal human colon mucosal cells. Oncogene Res 1987;1:149-
68.
7. Cartwright CA, Kamps MP, Meisler AI, Pipas JM, Eckhart W.
pp60c-src activation in human colon carcinoma. J Clin In-
vest 1989;83:2025-33.
8. Cartwright CA, Meisler AI, Eckhart W. Activation of the
pp60c-src protein kinase is an early event in colonic carci-
nogenesis. Proc Natl Acad Sci USA 1990;87:558-62.
9. Talamonti MS, Roh MS, Curley SA, Gallick GE. The c-src
oncogene participates in the development of human colo-
rectal liver metastases. Surg Forum 1991;42:422-4.
10. Talamonti MS, Roh MS, Curley SA, Gallick GE. Increase in
activity and level of pp60c-src in progressive stages of hu-
man colorectal cancer. J Clin Invest 1993;91:53-60.
11. Weber TK, Steele G, Summerhayes IC. Differential pp60c-src
activity in well and poorly differentiated human colon car-
cinomas and cell lines. J Clin Invest 1992;90:815-21.
12. Ottenhoff-Kalff AE, Rijksen G, van Beurden EA, Hennipman
A, Michels AA, Staal GE. Characterization of protein tyrosine
kinases from human breast cancer: involvement of the c-src
oncogene product. Cancer Res 1992;52:4773-8.
13. Wiener JR, Nakano K, Kruzelock RP, Bucana CD, Bast RC Jr.,
Gallick GE. Decreased Src tyrosine kinase activity inhibits
malignant human ovarian cancer tumor growth in a nude
mouse model. Clin Cancer Res 1999;5:2164-70.
14. Staley CA, Parikh NU, Gallick GE. Decreased tumorigenicity
of a human colon adenocarcinoma cell line by an antisense
expression vector specific for c-Src. Cell Growth Differ 1997;
8:269-74.
15. Ellis LM, Staley CA, Liu W, Fleming RY, Parikh NU, Bucana
CD, et al. Down-regulation of vascular endothelial growth
factor in a human colon carcinoma cell line transfected with
an antisense expression vector specific for c-src. J Biol Chem
1998;273:1052-7.
16. Pories SE, Hess DT, Swenson K, Lotz M, Moussa R, Steele G
Jr., et al. Overexpression of pp60c-src elicits invasive behav-
ior in rat colon epithelial cells. Gastroenterology 1998;114:
1287-95.
17. Sato H, Kita M, Seiki M. v-Src activates the expression of
92-kDa type IV collagenase gene through the AP-1 site and the
GT box homologous to retinoblastoma control elements. A
mechanism regulating gene expression independent of that by
inflammatory cytokines. J Biol Chem 1993;268:23460-8.
18. Ishidoh K, Taniguchi S, Kominami E. Egr family member
proteins are involved in the activation of the cathepsin L
gene in v-src-transformed cells. Biochem Biophys Res Com-
mun 1997;238:665-9.
19. Bell SM, Brackenbury RW, Leslie ND, Degen JL. Plasmino-
gen activator gene expression is induced by the src onco-
gene product and tumor promoters. J Biol Chem 1990;265:
1333-8.
20. Bell SM, Connolly DC, Maihle NJ, Degen JL. Differential
modulation of plasminogen activator gene expression by
oncogene-encoded protein tyrosine kinases. Mol Cell Biol
1993;13:5888-97.
21. Allgayer H, Wang H, Gallick GE, Crabtree A, Mazar A, Jones
T, et al. Transcriptional induction of the urokinase receptor
gene by a constitutively active Src. Requirement of an up-
stream motif (152/135) bound with Sp1. J Biol Chem
1999;274:18428-37.
22. Cartwright CA, Coad CA, Egbert BM. Elevated c-Src tyrosine
kinase activity in premalignant epithelia of ulcerative colitis.
J Clin Invest 1994;93:509-15.
23. Pyke C, Kristensen P, Ralfkiaer E, Grondahl-Hansen J, Erik-
sen J, Blasi F, et al. Urokinase-type plasminogen activator is
expressed in stromal cells and its receptor in cancer cells at
invasive foci in human colon adenocarcinomas. Am J Pathol
1991;138:1059-67.
24. Pyke C, Kristensen P, Ralfkiaer E, Eriksen J, Dano K. The
plasminogen activation system in human colon cancer:
messenger RNA for the inhibitor PAI-1 is located in endo-
thelial cells in the tumor stroma. Cancer Res 1991;51:4067-
71.
25. Hollas W, Boyd D. Urokinase-dependent proteolysis in cul-
tured colon cancer is directed by its receptor. Semin Thromb
Hemost 1991;17:225-30.
26. Reiter LS, Kruithof EK, Cajot JF, Sordat B. The role of the
urokinase receptor in extracellular matrix degradation by
HT29 human colon carcinoma cells. Int J Cancer 1993;53:
444-50.
27. Ganesh S, Sier CF, Heerding MM, Griffioen G, Lamers CB,
Verspaget HW. Urokinase receptor and colorectal cancer
survival. Lancet 1994;344:401-2.
28. Brieman L, Friedman JH, Olshen RA, Stone CJ. Classification
and regression trees. Belmont, CA: Wadsworth, 1984.
29. Kaplan EL, Meier P. Nonparametric estimation from incom-
plete observations. J Am Stat Assoc 1958;53:457-81.
30. Cox DR. Regression models and life tables. J Stat Soc 1972;
34:187-220.
350 CANCER January 15, 2002 / Volume 94 / Number 2
31. Dixon WJ, Brown MB, Engelman L. BMDP statistical soft-
ware. University of California Press, 1995.
32. Termuhlen PM, Curley SA, Talamonti MS, Saboorian MH,
Gallick GE. Site-specific differences in pp60c-src activity in
human colorectal metastases. J Surg Res 1993;54:293-8.
33. Han NM, Curley SA, Gallick GE. Differential activation of
pp60(c-src) and pp62(c-yes) in human colorectal carcinoma
liver metastases. Clin Cancer Res 1996;2:1397-404.
34. Irby RB, Mao W, Coppola D, Kang J, Loubeau JM, Trudeau
W, et al. Activating SRC mutation in a subset of advanced
human colon cancers. Nat Genet 1999;21:187-90.
35. Daigo Y, Furukawa Y, Kawasoe T, Ishiguro H, Fujita M, Sugai S,
et al. Absence of genetic alteration at codon 531 of the human
c-src gene in 479 advanced colorectal cancers from Japanese
and Caucasian patients. Cancer Res 1999;59:4222-4.
36. Laghi L, Bianchi P, Orbetegli O, Gennari L, Roncalli M,
Malesci A. Lack of mutation at codon 531 of SRC in ad-
vanced colorectal cancers from Italian patients. Br J Cancer
2001;84:196-8.
37. Wang NM, Yeh KT, Tsai CH, Chen SJ, Chang JG. No evidence
of correlation between mutation at codon 531 of src and the
risk of colon cancer in Chinese. Cancer Lett 2000;150:201-4.
38. Weiner TM, Liu ET, Craven RJ, Cance WG. Expression of
focal adhesion kinase gene and invasive cancer. Lancet
1993;342:1024-5.
39. Di Renzo MF, Olivero M, Giacomini A, Porte H, Chastre E,
Mirossay L, et al. Overexpression and amplification of the
met/HGF receptor gene during the progression of colorectal
cancer. Clin Cancer Res 1995;1:147-54.
40. Jessup JM, Gallick GE. The biology of colorectal carcinoma.
Curr Probl Cancer 1992;16:261-328.
41. Benistant C, Chapuis H, Mottet N, Noletti J, Crapez E, Bali
JP, et al. Deregulation of the cytoplasmic tyrosine kinase
cSrc in the absence of a truncating mutation at codon 531 in
human bladder carcinoma. Biochem Biophys Res Commun
2000;273:425-30.
42. Gold JS, Reynolds AB, Rimm DL. Loss of p120ctn in human
colorectal cancer predicts metastasis and poor survival.
Cancer Lett 1998;132:193-201.
43. Rajala RV, Dehm S, Bi X, Bonham K, Sharma RK. Expression
of N-myristoyltransferase inhibitor protein and its relation-
ship to c-Src levels in human colon cancer cell lines. Bio-
chem Biophys Res Commun 2000;273:1116-20.
44. Genda T, Sakamoto M, Ichida T, Asakura H, Hirohashi S.
Loss of cell-cell contact is induced by integrin-mediated
cell-substratum adhesion in highly-motile and highly-met-
astatic hepatocellular carcinoma cells. Lab Invest 2000;80:
387-94.
45. Noe V, Chastre E, Bruyneel E, Gespach C, Mareel M. Extra-
cellular regulation of cancer invasion: the E-cadherin-cate-
nin and other pathways. Biochem Soc Symp 1999;65:43-62.
46. Gutwein P, Oleszewski M, Mechtersheimer S, Agmon-Levin
N, Krauss K, Altevogt P. Role of Src kinases in the ADAM-
mediated release of L1 adhesion molecule from human
tumor cells. J Biol Chem 2000;275:15490-7.
47. Noritake H, Miyamori H, Goto C, Seiki M, Sato H. Overex-
pression of tissue inhibitor of matrix metalloproteinases-1
(TIMP-1) in metastatic MDCK cells transformed by v-src.
Clin Exp Metastasis 1999;17:105-10.
48. Bohuslav J, Horejsi V, Hansmann C, Stockl J, Weidle UH,
Majdic O, et al. Urokinase plasminogen activator receptor,
beta 2-integrins, and Src-kinases within a single receptor
complex of human monocytes. J Exp Med 1995;181:1381-90.
49. Konakova M, Hucho F, Schleuning WD. Downstream targets
of urokinase-type plasminogen-activator-mediated signal
transduction. Eur J Biochem 1998;253:421-9.
Src Activity: Prognostic in Colon Carcinoma/Allgayer et al. 351
